Original Article| Volume 9, ISSUE 6, P741-750, November 2015

Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: Results from the CHARON study

Published:August 01, 2015DOI:


      • Heterozygous familial hypercholesterolemia can lead to premature cardiovascular disease.
      • To prevent premature cardiovascular disease, statins should be initiated at an early age.
      • CHARON evaluated efficacy and safety of rosuvastin in children aged 6 to 17 years.
      • At 2 years, rosuvastatin 5–20 mg significantly reduced low-density lipoprotein cholesterol up to 45%.
      • Treatment was well tolerated with no adverse effects on growth or sexual maturation.


      Heterozygous familial hypercholesterolemia (HeFH) is an autosomal dominant disorder leading to premature atherosclerosis. Guidelines recommend initiating statins early to reduce low-density lipoprotein cholesterol (LDL-C). Studies have evaluated rosuvastatin in children aged ≥10 years, but its efficacy and safety in younger children is unknown.


      Children with HeFH and fasting LDL-C >4.92 mmol/L (190 mg/dL) or >4.10 mmol/L (>158 mg/dL) with other cardiovascular risk factors received rosuvastatin 5 mg daily. Based on LDL-C targets (<2.85 mmol/L [<110 mg/dL]), rosuvastatin could be uptitrated to 10 mg (aged 6–9 years) or 20 mg (aged 10–17 years). Treatment lasted 2 years. Changes in lipid values, growth, sexual maturation, and adverse events (AEs) were assessed.


      The intention-to-treat analysis included 197 patients. At 24 months, LDL-C was reduced by 43, 45, and 35% vs baseline in patients aged 6–9, 10–13, and 14–17 years, respectively (P < .001 for all groups). Most AEs were mild. Intermittent myalgia was reported in 11 (6%) patients and did not lead to discontinuation of rosuvastatin treatment. Serious AEs were reported by 9 (5%) patients, all considered unrelated to treatment by the investigators. No clinically important changes in hepatic biochemistry were reported. Rosuvastatin treatment did not appear to adversely affect height, weight, or sexual maturation.


      In HeFH patients aged 6–17 years, rosuvastatin 5–20 mg over 2 years significantly reduced LDL-C compared with baseline. Treatment was well tolerated, with no adverse effects on growth or sexual maturation.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Clinical Lipidology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Goldstein J.
        • Brown M.
        Familial hypercholesterolaemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol.
        Proc Natl Acad Sci U S A. 1973; 70: 2804-2808
        • Nordestgaard B.G.
        • Chapman M.J.
        • Humphries S.E.
        • et al.
        • European Atherosclerosis Society Consensus Panel
        Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Consensus statement of the European Atherosclerosis Society.
        Eur Heart J. 2013; 34: 3478-3490
        • Sjouke B.
        • Kusters D.M.
        • Kindt I.
        • et al.
        Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome.
        Eur Heart J. 2015; 1: 560-565
        • Marks D.
        • Thorogood M.
        • Neil H.
        • Humphries S.
        A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia.
        Atherosclerosis. 2003; 168: 1-14
        • Neil A.
        • Cooper J.
        • Betteridge J.
        • et al.
        Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study.
        Eur Heart J. 2008; 29: 2625-2633
        • Wiegman A.
        • Hutten B.A.
        • de Groot E.
        • et al.
        Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial.
        JAMA. 2004; 292: 331-337
        • Kusters M.
        • Hutten B.
        • McCrindle B.
        • et al.
        Design and baseline data of a paediatric study with rosuvastatin in familial hypercholesterolaemia.
        J Clin Lipidol. 2013; 7: 408-413
        • National Heart, Lung and Blood Institute
        Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: summary report.
        Pediatrics. 2011; 128: S213-S256
        • Wiegman A.
        • Gidding S.S.
        • Watts G.F.
        • et al.
        European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment.
        Eur Heart J. 2015; 36: 2425-2437
        • Cholesterol Treatment Trialists' (CTT) Collaboration
        Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
        Lancet. 2010; 376: 1670-1681
        • Avis H.
        • Vissers M.
        • Stein E.
        • et al.
        A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia.
        Arterioscler Thromb Vasc Biol. 2007; 27: 1803-1810
        • Vuorio A.
        • Kuoppala J.
        • Kovanen P.T.
        • et al.
        Statins for children with familial hypercholesterolemia.
        Cochrane Database Syst Rev. 2014; : CD006401
        • Avis H.
        • Hutten B.
        • Gagné C.
        • et al.
        Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia.
        J Am Coll Cardiol. 2010; 55: 1121-1126
        • Friedewald W.
        • Levy R.
        • Frederickson D.
        Estimation of concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge.
        Clin Chem. 1972; 18: 499-502
        • Couture P.
        • Brun L.D.
        • Szots F.
        • et al.
        Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia.
        Arterioscler Thromb Vasc Biol. 1998; 18: 1007-1012
        • Bertrais S.
        • Balkau B.
        • Charles M.A.
        • et al.
        Puberty-associated differences in total cholesterol and triglyceride levels according to sex in French children aged 10-13 years.
        Ann Epidemiol. 2000; 10: 316-323
        • Berenson G.S.
        • Srinivasan S.R.
        • Cresanta J.L.
        • Foster T.A.
        • Webber L.S.
        Dynamic changes of serum lipoproteins in children during adolescence and sexual maturation.
        Am J Epidemiol. 1981; 113: 157-170
        • Stein E.
        • Strutt K.
        • Southworth H.
        • Diggle P.J.
        • Miller E.
        • for the HeFH Study Group
        Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia.
        Am J Cardiol. 2003; 92: 1287-1293
        • McCrindle B.
        • Ose L.
        • Marais D.
        Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicentre, randomized, placebo-controlled trial.
        J Pediatr. 2003; 142: 74-80
        • de Jongh S.
        • Ose L.
        • Szamosi T.
        • et al.
        • Simvastatin in Children Study Group
        Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin.
        Circulation. 2002; 106: 2231-2237
        • Rodenburg J.
        • Vissers M.N.
        • Wiegman A.
        • et al.
        Statin treatment in children with familial hypercholesterolemia: the younger, the better.
        Circulation. 2007; 116: 664-668